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Abstract. Protein glycosylation perturbations are implicated 
in a variety of diseases, including cancer. Aberrant glycosyl‑
ation in cancer is frequently attributed to altered expression 
of polypeptide GalNAc transferases (GalNAc‑Ts) ‑ enzymes 
initiating mucin‑type O‑glycosylation. A previous study 
from our group demonstrated that one member of this family 
(GALNT3) is overexpressed in epithelial ovarian cancer (EOC), 
and GALNT3 expression correlated with shorter progression‑
free survival (PFS) in EOC patients with advanced disease. 
As considerable degree of redundancy between members of 
the GalNAc‑Ts gene family has been frequently observed, we 
decided to investigate whether other members of this family 
are essential in EOC progression. In silico analysis based on 
publically available data was indicative for altered expression 
of five GalNAc‑Ts (GALNT2, T4, T6, T9 and T14) in ovarian 
high‑grade serous carcinoma (HGSC) samples compared to 
non‑tumoral (control) ovarian tissue. We analyzed protein 
expression of these GalNAc‑Ts in EOC cells and tumors by 
western blotting, followed by immunohistochemical (IHC) 
evaluation of their expression in EOC tumor and control 
samples using tissue microarrays (TMAs). Western blot 
analyses were indicative for low expression of GALNT2 and 
strong expression of GALNT6, T9 and T14 in both EOC cells 
and tumors. These observations were confirmed by IHC. 
GALNT2 displayed significantly lower expression, while 
GALNT6, GALNT9 and GALNT14 showed significantly 
higher expression in HGSC tumors compared to control tissue. 
Importantly, GALNT6 and GALNT14 expression correlated 
with poor prognosis of serous EOC patients. Moreover, our 
results suggest for overlapping functions of some GalNAc‑Ts, 
more specifically GALNT3 and GALNT6, in directing EOC 
progression. Our results are indicative for a possible implication 
of different members of the GalNAc‑T gene family in modu‑
lating EOC progression, and the potential use of GALNT6 and 
GALNT14 as novel prognostic EOC biomarkers. These data 
warrant future studies on the role of members of the GalNAc‑Ts 
gene family in ovarian tumorigenesis.
Introduction
Epithelial ovarian cancer (EOC) accounts for 4% of all 
cancers in women and is the leading cause of death from 
gynecologic malignancies (1). Despite medical and surgical 
improvements, long‑term survival rates for EOC patients 
with advanced disease remain disappointing, primarily due 
to its asymptomatic nature and the lack of reliable methods 
for early diagnosis (2,3). Indeed, most women are diagnosed 
with EOC when micro‑ and macro‑metastases are already 
present and currently, the 5‑year EOC survival rate is rather 
disappointing (<40%) (1). Thus, the identification of novel 
pro‑metastatic EOC molecules and associated pathways could 
provide additional therapeutic targets for improved manage‑
ment of this deadly disease.
There are many documented studies investigating 
different post‑translational modifications (PTMs) and their 
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association with cancer; among these, aberrant glycosylation 
has displayed rather important roles in cancer progres‑
sion (4,5), including EOC dissemination (6,7). Mucin‑type 
O‑glycosylation of proteins represents the most diverse PTM 
form, and is considered to be a conserved type of glycosyl‑
ation found in many species and organ types (8). This type of 
PTM is rather complex and involves the transfer of different 
monosaccharides to each of the six O‑linked glycans (9). 
O‑glycosylation is initiated by 20 GalNAc‑transferases, a 
family of enzymes known as the uDP N‑acetylgalactosamine: 
polypept ide N‑acetyl galactosaminyl t ransferases 
(GalNAc‑Ts) (9), which are responsible for the transfer of the 
monosaccharide GalNAc from uDP‑GalNAc to the hydroxyl 
group of the serine, threonine or tyrosine residues found 
in the target protein substrate (10). Interestingly, the genes 
comprising this family of enzymes show tissue‑specific 
expression (11,12), but also have overlapping substrate 
specificities, suggestive for partial functional redundancy in 
their function (11). Several in vitro studies have shown that 
GalNAc‑Ts are differentially expressed in cells and tissues 
during development (9). Aberrant GalNAc‑Ts expression 
patterns have been frequently observed in cancer (13), which 
warrants further studies on the possible implications of these 
enzymes in tumor progression and their potential use as 
therapeutic targets and/or prognostic markers (14).
We have previously identi f ied the GalNAc‑T3 
(GALNT3) gene as a potential EOC oncogene, highly 
expressed in advanced disease, as GALNT3 expression was 
significantly associated with poor outcome (15). We also 
demonstrated that in EOC cells, GALNT3 might directly 
alter biosynthesis and/or aberrant glycosylation of different 
O‑glycoproteins that could play an essential role in EOC 
dissemination (15‑17). however, to date, no other studies have 
comprehensively assessed the implications of other members 
of the GalNAc‑Ts gene family in EOC dissemination. We 
thus decided to examine the role of some of the GalNAc‑Ts 
that have been reported to play essential roles in the etiology 
of different cancer types. Five members of this gene family 
(GALNT2, T4, T6, T9 and T14) have previously displayed 
significant alterations in their expression in different cancer 
types (reviewed in ref. 7). In silico analysis of the GalNAc‑Ts 
expression profiles from publicly available data were also 
indicative for overexpression of some of these GalNAc‑Ts 
(including GALNT4, T6, and T14), as well as GALNT3, in 
ovarian HGSC samples.
The above data prompted us to investigate the expression 
levels of these five GalNAc‑Ts (GALNT2, T4, T6, T9 and 
T14) in EOC cells and EOC tumor tissues, and to correlate 
their expression with the corresponding clinicopathological 
characteristics. To our knowledge this is the first report that 
comprehensively examines the expression profiles of several 
GalNAc‑Ts in EOC with the perspective of identifying novel 
prognostic factors for this deadly disease. We show that most 
of the GalNAc‑Ts analyzed (including GALNT2, T6, T9 and 
T14) displayed altered expression in EOC cells and tumors 
importantly, our data are indicative for a significant association 
of two GalNAc‑Ts (GALNT6 and T14) with progression‑
free survival (PFS) values of EOC patients, suggestive for 
oncogenic functions of these two enzymes in EOC, and their 
potential use as novel EOC prognostic biomarkers.
Materials and methods
Patient cohort. Patients included in this study were oper‑
ated between January 1998 to December 2015 for advanced 
ovarian cancer at the ChuQ hôtel‑Dieu hospital in Quebec 
City, Canada. Inclusion criteria were: serous papillary carci‑
noma histology, FIGO stages II, III or Iv and chemotherapy 
received after the surgery (see Table I for detailed clinico‑
pathological characteristics). All tumors were histologically 
classified according to the criteria defined by the World health 
Organization (18). Disease progression was evaluated following 
the guidelines of the Gynecology Cancer Intergroup (18). PFS 
was defined as the time from surgery to the first observation 
of disease progression, recurrence or death. The follow‑up 
was available until death or to the date the study was closed 
(30 December 2016). Nineteen non‑tumoral (control) ovarian 
samples were derived from women subjected to hysterectomy 
with oophorectomy due to non‑ovarian pathologies.
Ethics statement approval and consent to participate. The 
study was approved by the Clinical Research Ethics Committee 
of the hotel‑Dieu de Québec hospital, and all patients signed 
Table I. Detailed patients' clinicopathological characteristics.
variable range N/Total %
Age (years) ≥65 54/162 33
 <65 108/162 67
Median age 60
Tissue/tumor type Normal 18/162 11
 LMP 13/162   8
 high‑grade 131/162 81
Grade 3 126/131 96
 2 5/131   4
Stage II 5/131   4
 III 92/131 70
 Iv 34/131 26
Chemotherapya Platinum+Taxol 120/131 92
 Other 11/131   8
CA125b (u/ml) ≥800 59/118 50
 <800 59/118 50
PFSc (months) 0‑6 53/124 43
 7‑24 44/124 35
 >25 27/124 22
aAll patients were subjected to adjuvant therapy. bExtended follow‑up, 
including CA125 values, were available for 118 patients. CA125 values 
correspond to the baseline serum concentrations of EOC patients. 
cExtended follow‑up, including progression‑free survival (PFS) values, 
were available for 124 patients. PFS is defined as the time from surgery 
to the first observation of disease progression, recurrence or death. The 
follow‑up was available until death or to the date the study was closed. 
LMP, low‑malignant potential.
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an informed consent for voluntary participation and agreed to 
report individual patient data.
Cell culture. The EOC cell lines SKOv3 and CaOv3 were 
purchased from the American Tissue Type Collection; 
Ov‑90, Ov2008, TOv‑112 and TOv‑21 cell lines were a 
kind gift from Dr Anne‑Marie Mes‑Masson (Montreal 
university), A2780s and A2780cp cell lines were a kind gift 
from Dr Benjamin Tsang (Ottawa university), the OvCAr4 
cell line was a kind gift from Dr Stephan Gobeil (Laval 
University), and the two human ovarian surface epithelial 
(hOSE) cell lines; hOSE 6.3 and 17.1 were a kind gift from 
Dr Francis Jacob (university hospital Basel). The cell lines 
were passaged in different culture media supplemented with 
10% fetal bovine serum, and 1% penicillin streptomycin or 
50 µg/ml of gentamicin as described previously (15).
Western blotting. Western blot analysis was performed as 
previously described (15). Briefly, protein lysates of the EOC 
and HOSE cell lines, were prepared by suspending cell pellets 
in Laemmli sample buffer containing 5% β‑mercaptoethanol. 
Ovarian tumor tissue and non‑tumoral tissues were homog‑
enized and sonicated in rIPA buffer [50 mM Tris (ph 7.4), 
150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% 
Triton x‑100] containing protease and phosphatase inhibitors, 
samples were then incubated on ice for 15 min. Protein samples 
from cells and tissues were measured using a BCA protein 
assay kit (Thermo Scientific Pierce, rockford, IL, uSA). BSA 
standard or samples (20 µl) were transferred to a 96 well plate 
to which 200 µl working reagent was added (working reagent 
50:1 ratio of assay reagents A and B). The plate was incubated 
for 30 min at 37˚C, the plates were then analyzed with a spec‑
trophotometer at 560 nm [iMArK microplate reader (Bio‑rad 
hercules, CA, uSA)]. After centrifugation at 13,300 rpm for 
15 min at 4˚C, the supernatant was taken and 20‑30 µg of 
the protein were used for sample preparation. Protein lysates 
were separated by 6‑12% Tris‑glycine gel electrophoresis and 
transferred onto a polyvinylidene difluoride membrane using 
a semidry apparatus (Bio‑rad Laboratories, Mississauga, ON, 
Canada). The membrane was blocked with 4% non‑fat dry 
milk in TBST (20 mmol/l Tris‑hCl, 0.5 M NaCl and 0.1% 
Tween‑20), and the membranes were incubated overnight with 
the primary antibody at 4˚C or 1 h at rT (for a list of all the 
antibodies used in this study refer to Table II). After 3x15 min 
washes with TBST (20 mmol/l Tris‑hCl, 0.5 M NaCl and 
0.1% Tween‑20) at room temperature, the membranes were 
incubated with horseradish peroxidase‑conjugated secondary 
antibody and detected with ECL solution (Thermo Fisher 
Scientific, Waltham, MA, uSA).
Tissue micro arrays (TMAs) and immunohistochemistry (IHC). 
TMAs were constructed as previously described (15). Briefly, 
one representative block of each ovarian tumor and control 
ovarian tissue was selected for the preparation of the tissue 
arrays. Three 0.6‑mm cores of tumor were taken from each 
tumor block and placed, 0.4 mm apart, on a recipient paraffin 
block using a commercial tissue arrayer (MTA‑II arrayer) 
(Beecher Instruments, Silver Spring, MD, uSA). The cores 
were randomly placed on one of three recipient blocks to avoid 
evaluation biases.
IhC analyses were performed, as previously described (15). 
Briefly, 4‑µm tissue sections were deparaffinised and rehy‑
drated in graded alcohols, then incubated with blocking serum 
for 20 min. Following treatment with 3% h2O2 for 10 min 
to quench the endogenous peroxidise activity, sections were 
incubated with the primary antibody overnight at 4˚C (for a 
list of all the antibodies used in this study refer to Table II). 
Incubation and detection with SignalStain 3,3'‑diaminoben‑
zidine (DAB) Substrate kit (IDetect universal Mouse Kit 
hrP‑DAB; ID  Labs, Buffalo, NY, uSA) were done according 
to the manufacturer's instructions. Sections were then counter‑
stained with hematoxylin. Images were acquired using a Leica 
Confocal Scope (TCS SP5 x; Leica Microsystems, Exton, PA, 
USA) and analyzed via the Leica Application Suite Software 
(Leica Microsystems).
Scoring and statistical analysis. Protein expression was 
scored according to intensity (value of 0 for absence, 1 for low, 
2 for moderate, and 3 for high) of staining based on manual 
visualization. A composite score was defined as the product 
Table II. Dilution and technique used for each antibody in IhC and western blot analyses.
Antibody Species Dilution TMA Company retrieval Incubation TMA Dilution WB Incubation WB
Anti‑GALNT2 rabbit 1:50 Abcam Microwave 4˚C overnight 1:1,000 4˚C overnight
Anti‑GALNT4 rabbit 1:100, 1:50, 1:25 Proteintech Microwave/ 4˚C overnight 1:500 4˚C overnight
    pronase
Anti‑GALNT6 Mouse 1:75 Abcam Microwave 4˚C overnight 1:1,000 4˚C overnight
Anti‑GALNT9 rabbit 1:100 LifeSpan Microwave 4˚C overnight 1:1,000 4˚C overnight
   BioScience
Anti‑GALNT14 rabbit 1:100 Abcam Microwave 4˚C overnight 1:1,000 4˚C overnight
Anti‑β‑actin Mouse N/A Santa Cruz N/A N/A 1:2,000 1 h/room
       temperature
IhC, immunohistochemistry; TMA, tissue microarray; WB, western blotting.
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of staining intensity (nuclear, cytoplasmic, or membranous 
depending on the expected staining). All slides were inde‑
pendently scored in a blinded manner by 2 observers, and 
the integration was >85%. In case of differences between the 
2 scorings, the core was re‑evaluated to reach a consensus. 
The relationship between the protein expression of the listed 
genes in HGSC and LMP tumors, and control ovarian tissues 
was evaluated by the Wilcoxon two‑sample test. A significant 
association was considered when p‑values were <0.05.
Multiple correspondence analysis (MCA) was used to 
produce 2‑dimensional displays of similarities of the relative 
expression patterns amongst the five GalNAc‑Ts staining 
intensity in the different patient samples. MCA statistical 
analyses were carried out using SPSS software, version 13.0. 
Survival analysis results were visualized using Kaplan‑Meier 
survival curve analysis (SPSS software, version 13.0). A 
Kaplan‑Meier curve and the log‑rank test were performed 
based on PFS values to test the effect of the intensity of the gene 
(3, 2 vs. 0, 1) on disease progression. The relationship between 
the GalNAc‑Ts staining intensity and PFS was determined 
by the non‑parametric Mantel‑Cox log‑rank test to compare 
survival distributions (SPSS software, version 13.0). Bivariate 
and multivariate analyses, taking into account standard or 
strongly associated prognostic variables, were performed to 
identify independent prognostic factors and a statistic test 
p‑value of <0.05 was considered statistically significant.
Results
Analyses of the expression profiles of different members of the 
GalNAc‑Ts family in both ovarian HGSC tumors and EOC 
cell lines. Initially, we investigated GalNAc‑Ts expression 
profiles from publicly available data generated from samples 
found in the independently derived Affymetrix GeneChip 
human Genome u133 Plus 2.0 [hG‑u133_Plus_2] (19). The 
in silico data examined were based on global gene expres‑
sion analysis of differentially expressed candidate mRNAs 
in 21 moderately differentiated (MD) and poorly differenti‑
ated (PD) serous ovarian carcinomas (SOC) (MD/PD SC), 
13 serous ovarian borderline (SOBT), and seven superficial 
scrapings from normal ovary (SNO) samples (19). These anal‑
yses showed significant correlation and high fold change in 
the overexpression of several GalNAc‑Ts in the SOC samples 
compared to both the SBOT and SNO samples including: 
GALNT3, GALNT4, GALNT6, and GALNT14. Based on 
the above in silico analyses, as well as on literature data (as 
can be seen in Introduction), we decided to further proceed 
with investigating the expression levels of five GalNAc‑Ts 
(GALNT2, T4, T6, T9 and T14) in EOC specimens by western 
blotting. The protein expression levels of these GalNAc‑Ts 
were initially analyzed in nine EOC cell lines and in two 
hOSE cell lines (Fig. 1A). As seen from Fig. 1A, GALNT2 
displayed lack of expression in seven EOC cell lines studied 
and quite a weak expression in SKOv3 and TOv112 EOC 
cells, compared to its rather strong expression in the two 
control HOSE cell lines, indicative for a suppression of this 
enzyme in EOC cells. GALNT4 showed very weak, or lack of 
expression in all (both EOC and HOSE) cell lines analyzed. 
GALNT6 expression was highly observed in three EOC cell 
lines (TOv21, CaOv3 and OvCAr4) while showing no, or 
weak expression in the two hOSE cell lines (Fig.1A). Finally, 
both GALNT9 and GALNT14 displayed very high expression 
in all EOC cell lines and almost lack of expression in the 
hOSE cell lines (Fig. 1A).
Further analyses of the protein expression levels of the 
selected GalNAc‑Ts in four ovarian HGSC tumor samples and 
four control ovarian tissue samples were quite confirmatory 
to the data obtained with the EOC and HOSE (control) cell 
lines (Fig. 1B). Indeed, GALNT2 showed a relatively high 
expression in all control samples, while no expression was 
observed in the hGSCs, while GALNT4 showed an analogous 
pattern of rather weak or no expression between control tissues 
and hGSC tumors. Correspondingly, GALNT6 showed a rela‑
tively high expression in the HGSCs tumor samples compared 
Figure 1. GalNAc‑Ts expression in EOC cells and EOC tumors. (A) Western blot analysis of endogenous GALNT2, T4, T6, T9 and T14 protein expression in 
different EOC cell lines and the hOSE cell lines. (B) Western blot analysis of endogenous GALNT2, T4, T6, T9 and T14 protein expression in 4 hG ovarian 
samples (OG1‑OG4) and 4 non‑tumoral ovarian tissue (control tissue) samples (NOv1‑NOv4). β‑actin was used as a loading control. EOC, epithelial ovarian 
cancer; hOSE, human ovarian surface epithelial; NOv, normal ovarian; Ov, ovarian tumor.
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Figure 2. GalNAc‑Ts protein expression in hG samples compared to LMP and non‑tumoral ovarian samples. (A) a, GALNT2 staining patterns in representative 
cores in control ovarian tissues, LMP tumors and hG tumors. b, Box‑plot presentation of GALNT2 protein expression levels in control ovarian tissues, LMP 
tumors and hG tumors. (B) a, GALNT4 staining patterns in representative cores in control ovarian tissues, LMP tumors and hG tumors. b, Box‑plot presentation 
of GALNT4 protein expression levels in control ovarian tissues, LMP tumors and hG tumors. (C) a, GALNT6 staining patterns in representative cores in control 
ovarian tissues, LMP tumors and hG tumors. b, Box‑plot presentation of GALNT6 protein expression levels in control ovarian tissues, LMP tumors and hG 
tumors. (D) a, GALNT9 staining patterns in representative cores in control ovarian tissues, LMP tumors and hG tumors. b, Box‑plot presentation of GALNT9 
protein expression levels in control ovarian tissues, LMP tumors and hG tumors. (E) a, GALNT14 staining patterns in representative cores in control ovarian 
tissues, LMP tumors and hG tumors. b, Box‑plot presentation of GALNT14 protein expression levels in control ovarian tissues, LMP tumors and hG tumors. 
All p‑values were derived from log‑rank tests. Error bars denote standard deviation of each mean calculation. hG, high‑grade; LMP, low‑malignant potential.
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to control tissues, and again, GALNT9 and GALNT14 
displayed the strongest overexpression levels in HGSCs, rela‑
tive to the controls (Fig. 1B).
IHC analysis of the expression patterns of five GalNAc‑Ts 
in numerous EOC tumors using TMAs. We next proceeded 
with evaluating the GalNAc‑Ts expression levels by IHC 
in TMAs comprising triplicate cores of 131 hGSCs and 
13 LMP tumors, and including 18 control ovarian tissue 
specimens. Table I shows the major clinical characteristics 
of these patients for whom extensive follow‑up clinical data 
were available. The age ranged from 38 to 91 years (median: 
60 years). hGSC tumors were grade 3 [126 patients (96%) and 
grade 2 (5 patients (4%)]. Grade 3 tumors included stage III 
(70%) and stage Iv (26%) tumors, while grade 2 tumors 
included stage II (4%). Most patients (92%) received standard 
treatment of cytoreductive surgery followed by platinum/
taxane chemotherapy regimens. The median baseline CA125 
was ~800. Forty‑three percent of the patients had a progres‑
sion or a recurrence within the first 6 months of follow‑up; 
for 35% of the patients the PFS interval was in the range of 
7 to 24 months, and 22% of the patients displayed PFS values 
>25 months. The mean score for expression was defined by 
the extent and intensity of immunohistochemistry staining 
for GALNT2, T4, T6, T9 and T14 (Fig. 2). As expected, 
GALNT2 displayed highly significant expression (strong 
cytoplasmic granular staining) in control tissues compared 
to negative staining in both LMP (p<0.0001) and hGSC 
tumors (p<0.0001) (Fig. 2A). As previously, GALNT4 showed 
negative expression in all cases (tumor samples and control 
tissues), despite repeated attempts with various retrieval 
systems, antibody concentration, incubating time, or signal 
enhancements systems (Fig. 2B). GALNT6 showed a strong 
diffuse cytoplasmic staining which was exclusively present 
in hGSCs compared to control tissues (p=0.0001) and LMP 
tumors (p<0.0001) (Fig. 2C). A similar expression pattern 
was also observed for GALNT9 and GALNT14, as both 
these GalNAc‑Ts were significantly overexpressed in hGSC 
tumors, when compared to control tissues (p<0.0001), and 
(p<0.0001) respectively (Fig. 2D and E); however, GALNT9 
also displayed significant overexpression in LMP tumors 
compared to control samples (p=0.0146) (Fig. 2D), while 
no significant difference in GALNT14 protein expression 
was observed between LMP tumors and control tissues 
(p=0.0859) (Fig. 2E).
The above results, as well as data from our previous 
study (15) are indicative for the simultaneous overexpression 
of several GalNAc‑Ts in EOC cell lines and tumor tissues 
(including GALNT3, T6, T9 and T14). Since a considerable 
degree of redundancy between the different members of the 
GalNAc‑Ts gene family has been frequently observed (20), 
we decided to apply the MCA approach in order to more 
deeply investigate the extent of overlapping expression of 
these GalNAc‑Ts among the EOC tumor samples included 
in this study. Two quantitative variables are included in the 
analysis based on staining intensity: i) for positive staining 
in patient samples, and ii) for negative staining in patient 
samples. The two dimensions of the MCA explained 42.27% 
(dimension 1) and 19.32% (dimension 2) of the total data vari‑
ability, respectively (Fig. 3A). These analyses were indicative 
for a strong and a highly overlapping relationship between 
GALNT3 and GALNT6, as additionally, some overlapping 
relationship between GALNT6 and GALNT9 cannot be 
excluded (Fig. 3A). GALNT14 showed the highest diversity 
between staining 1 and 2, with no observed overlap with the 
other 4 genes (Fig. 3A). GALNT2 confirmed our previous data 
showing a complete inverse relationship to the other 4 genes, 
as GALNT2 staining expression 1 and 2 showed a high inverse 
correlation to expression pattern observed for GALNT14, 
and overall differential expression to those of GALNT3, 
T6 and T9 (Fig. 3A). The MCA‑suggested GALNT3/T6 
redundancy was further confirmed by examining protein 
Figure 3. (A) Multiple correspondence analyses (MCA) of the relationship of the GalNAc‑Ts expression in the hG ovarian tissue samples. Two major groups, 
separated by the first and second components, are observed. The first group includes the genes GALNT6 and T9 showing a somewhat overlapping expression 
pattern in the cohort of patients examined in the study. The second group indicates the inverse correlation observed between GALNT2 and GALNT14. For 
each analysis, the percentage of variance explained by the first two dimensions is indicated in parenthesis. (B) Western blot analysis of GALNT3, T6, T9 and 
T14 expression in control (Ctrl) and GALNT3 knockdown (KD) A2780s clones. β‑actin was used as a loading control. HG, high‑grade.
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expression profiles of GALNT6, T9 and T14 in the GALNT3 
knockdown (KD) clone, previously generated in the EOC cell 
line A2780s (15). As shown in Fig. 3B, we observed a clear 
upregulation in GALNT6 protein expression in the GALNT3 
KD clone, while no expression alterations were observed for 
both GALNT6 and T14.
Association of GalNAc‑Ts expression with clinicopatholog‑
ical data. We further proceeded to investigate the prognostic 
values of the four differentially expressed GalNAc‑Ts (T2, 
T6, T9 and T14) in EOC patients, as we evaluated the 
relationship between the TMA immunostaining of the 4 
GalNAc‑Ts and the patient PFS data using Kaplan‑Meier 
survival curve analyses. PFS follow‑up data were available for 
124 patients (Table I). The analyses were based on the staining 
intensities: low (includes staining levels of <2) and high 
(includes staining levels of >2) (Fig. 4). No significant differ‑
ences were observed between GALNT2 and T9 expression 
levels and the patient PFS values (log‑rank=2.715, p=0.099) 
and (log‑rank=0.995, p=0.319) respectively (Fig. 4A and C), 
which suggests that staining intensities for both GALNT2 
and T9 in pre‑treatment surgical EOC specimens are not 
predictive of PFS. however, there was a significant association 
between PFS and the expression of the two GalNAc‑Ts T6 and 
T14 (log‑rank=5.119, p=0.024) and (log‑rank=5.770, p=0.016) 
respectively (Fig. 4B and D).
Bivariate and multivariate analyses to predict PFS were 
also performed on all the 4 genes. Multivariate analyses 
taking into account standard or strongly associated prognostic 
variables (age, grade, stage and initial CA125) were performed 
Figure 4. Kaplan‑Meier progression‑free survival curves showing the association between GalNAc‑Ts expression patterns and prognosis in hG ovarian cancer. 
Kaplan‑Meier survival curve analysis of HG cases for progression‑free survival (PFS), presented as survival probability, of patients whose tumors show a 
defined staining pattern. For evaluation of GalNAc‑Ts staining, hG ovarian cancer subjects were divided into two groups, those with positive staining (3 or 
2 gene staining intensity) defined here as 1,00 on the Kaplan‑Meier curves and those with negative staining (1 or 0 gene staining intensity) defined here as 0.00 
on the Kaplan‑Meier curves. The staining pattern for (A) GALNT2 protein, negative (n=101), and positive (n=15). (B) GALNT6 protein, negative (n=60), and 
positive (n=56). (C) GALNT9 protein, negative (n=52), and positive (n=64). (D) GALNT14 protein, negative (n=19), and positive (n=97). All p‑values were 
derived from log‑rank tests. hG, high‑grade.
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to identify independent prognostic factors. Multivariate 
analyses showed a significant association for both GALNT6 
and GALNT14 and the higher risk of progression (hr, 1.672; 
CI, 1.043‑2.682; p=0.033) and (hr, 2.163; CI, 1.032‑4.534; 
p=0.041) respectively (Table III), but not for GALNT2 
and GALNT9 (hr, 0.339; CI, 0.103‑1.119; p=0.076) and 
(hr, 1.470; CI, 0.939‑2.300; p=0.092) respectively (Table III). 
Taken together, our findings indicate that GALNT6 and T14 
may represent useful markers to predict PFS of women with 
high grade serous EOC.
Discussion
Accumulating data are indicative for the important role of 
glycosylation perturbations in carcinogenesis, including also 
the abnormal expression of glycans, exclusively involved in 
embryonic development under normal conditions (21). Glycan 
alterations can be associated with cancer cell signaling and 
communication, tumor cell dissociation, migration and inva‑
sion, cell‑matrix interactions, tumor angiogenesis, immune 
modulation and metastasis formation (22,23), and can serve as 
important biomarkers and/or therapeutic targets (24).
Altered expression of glycans in cancer is frequently 
attributed to aberrant expression of different members of 
the GalNAc‑Ts family in malignant tumors compared to 
non‑tumoral tissue (7,14). The deregulation in the expression 
of the different GalNAc‑Ts allows them to play diverse roles 
in carcinogenesis (14). We have previously reported that one 
member of these GalNAc‑Ts (GALNT3) represents a poten‑
tial EOC oncogene, as its expression significantly correlated 
with shorter PFS intervals in EOC patients with advanced 
disease (15); however, data concerning the implication of other 
members of the GalNAc‑Ts gene family in EOC dissemination 
are rather scarce. Indeed, only one study was suggestive for a 
possible role of GALNT14 in mediating the malignant behavior 
of EOC cells (25). Otherwise, some of the most extensively 
studied GalNAc‑Ts in cancer include GALNT2, T4, T6, T9 
and T14 (7), which represent the transferases included in the 
present study. Thus, concerning GALNT2, only one study is 
suggestive for a possible oncogenic role of this transferase in 
oral cancer (26), while other studies in different cancer types, 
including neuroblastoma, liver and gastric cancer, are strongly 
supportive for a role of GALNT2 in suppressing tumorigen‑
esis (27‑29). GALNT4 has also displayed discrepant roles in 
different cancers, as an implication of GALNT4 in breast 
carcinogenesis has been repeatedly demonstrated (30‑32); 
however low GALNT4 expression was associated with poor 
PFS and overall survival of clear cell renal cell carcinoma 
patients (33). GALNT6 has been extensively studied for 
its implication in the malignant transformation and metas‑
tasis of epithelial cancers (34‑37), and especially in breast 
cancer (38‑40), where GALNT6 has been suggested as a novel 
marker for breast cancer detection and potential therapeutic 
target (41‑44). Similarly to GALNT2 and T4, literature data 
for the role of GALNT9 in carcinogenesis is rather contradic‑
tory, since a protective role of GALNT9 was suggested in 
neuroblastoma and breast cancer dissemination (45,46), while 
a recent report was indicative for an oncogenic function of 
this enzyme in colorectal cancer (47). Interestingly, GALNT9 
was among the genes identified as potentially hypomethyl‑
ated and overexpressed in advanced EOC as reported in our 
previous study (48). Finally, GALNT14 has been characterized 
as an oncogene in breast and lung cancer (49‑51); moreover, 
recent data are strongly indicative for a role of this transferase 
in mediating chemotherapy resistance in different cancer 
types (52‑58).
These reports are indicative for either protective or tumori‑
genic roles of the different GalNAc‑Ts in cancer, suggesting 
a highly complex and rather specific O‑glycosylation pattern 
of glycoproteins in the different cancer types. In this study 
we initially analyzed the expression levels of the selected five 
members of the polypeptide GalNAc‑Ts family in EOC cell 
lines and EOC tumor samples (HGSCs) by western blotting. 
Similar, if not identical patterns of expression were observed 
Table III. Cox regression analysis to predict progression‑free survival (PFS).
 Crude Adjusted
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Marker value Frequency Event hr 95% CI P‑value hra 95% CIb P‑value
  N (%) n (%)
GALNT2 Negative 101 (87.1%) 78 (77.2%) 1.0   1.0
 Positive 15 (12.9%) 11 (73.3%) 0.599 0.317‑1.130 0.113 0.339 0.103‑1.119 0.076
GALNT6 Negative 60 (51.7%) 40 (66.7%) 1.0   1.0
 Positive 56 (48.3%) 49 (87.5%) 1.596 1.047‑2.434 0.030 1.672 1.043‑2.682 0.033
GALNT9 Negative 52 (44.8%) 37 (71.2%) 1.0   1.0
 Positive 64 (55.2%) 52 (81.3%) 1.232 0.807‑1.880 0.334 1.470 0.939‑2.300 0.092
GALNT14 Negative 20 (17.2%) 11 (55.0%) 1.0   1.0
 Positive 96 (82.8%) 78 (81.3%) 2.185 1.117‑4.275  0.022 2.163 1.032‑4.534 0.041
aAdjusted for age, stage, grade, and baseline CA125. The hazards models were applied to adjust for the baseline patients' characteristics. bThe 
confidence interval was based on the arithmetic mean of the gene expression values of the selected cases from this study. hr, hazard ratio; 
CI, confidence interval. Bold, statistically significant.
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for these GalNAc‑Ts in both EOC cell lines and EOC tumors, as 
GALNT2 displayed very low or lack of expression in all EOC 
specimens studied, compared to control samples (including 
HOSE cells and non‑tumoral ovarian tissues), while the 
expression levels of GALNT6, T9 and T14 were significantly 
higher in EOC cells and EOC tumors, as compared to very 
low/lack of expression in the corresponding controls (Fig. 1). 
Only GALNT4 showed very subtle, or absence of any expres‑
sion in all EOC and control specimens analyzed, indicative for 
no implications of this enzyme in EOC progression (Fig. 1). 
These observations were further confirmed by performing 
IHC analysis of the protein expression levels in numerous EOC 
tumors and control tissues, using TMAs. Indeed, GALNT6, 
T9 and T14 exhibited very strong staining in hGSC tissues 
and very weak/no staining in the LMP tumors and control 
tissues, while GALNT2 displayed a rather inverse staining 
pattern indicative for a subtle or no expression in both HGSC 
and LMP tumors, compared to relatively strong expression 
in control tissues (Fig. 2). Again, lack of any staining was 
observed for GALNT4 in all (EOC tumor and control) tissue 
samples analyzed (Fig. 2). With the exception of GALNT4, 
our data are rather in accordance with previous studies for 
the roles of these GalNAc‑Ts in different carcinoma types 
as summarized above, and suggest for a possible correlation 
of GALNT6, T9 and T14 expression with EOC progression, 
while a putative protective role of GALNT2 in EOC dissemi‑
nation cannot be excluded.
Moreover, Kaplan‑Meier survival curves and consecutive 
Cox‑regression analyses revealed that the expression levels of 
two of the GalNAc‑Ts analyzed (GALNT6 and GALNT14) 
were significantly related with poor PFS in the studied cohort 
of hG serous EOC patients (Fig. 4B and D and Table III), 
which suggests the putative use of these two transferases as 
novel prognostic serous EOC biomarkers. These results, as 
well as data from our previous study (15), are indicative for 
the significant inverse association of three members of the 
GalNAc‑Ts gene family (GALNT3, T6 and T14) with disease 
progression in HGSC patients.
Furthermore, the simultaneous overexpression of four 
GalNAc‑Ts (GALNT3, T6, T9 and T14) in advanced EOC 
raises the question about the specific and/or redundant 
functions of the members of this gene family in normal and 
pathological conditions, including EOC. Notably, it is known 
that the different GalNAc‑Ts do have partially overlapping 
but distinct substrate specificities, which may result in these 
GalNAc‑Ts having partial functional redundancy (59). So far, 
twenty members of the human GalNAc‑Ts gene family have 
been identified (20), as such an abundance of GalNAc‑Ts could 
provide substantial biosynthetic back‑up. Although different 
GalNAc‑Ts are differentially expressed within tissues, 
between cells, within a single tissue, and in different patterns 
at different stages in the development and differentiation, it is 
now becoming clear that a subset of the GalNAc‑Ts display both 
distinct and overlapping substrate specificities (11,13). Some 
of the mammalian GalNAc‑transferase isoforms have been 
grouped into subfamilies based on their high homology (11,20). 
One such example is the human subfamily comprised of 
GALNT3 and GALNT6, displaying 65% homology in their 
coding sequence, although this homology does not provide 
complete functional redundancy (59). Interestingly, GALNT6 
displayed quite similar oncogenic functions in breast cancer 
(modulating aberrant O‑glycosylation and MuC1 stabiliza‑
tion) (39), as those found by us for GALNT3 in EOC (15). 
Increased GALNT3 and T6 co‑expression has been detected 
in pancreatic (60) and renal (61) carcinomas, suggestive for 
GALNT3/T6 complementary correlations. As shown (60,61), 
the upregulation of GALNT3 within the malignant transfor‑
mation and progression of these cancers could partly depend 
on that of GALNT6 in both synergistic and compensatory 
ways. Moreover, not a separate GALNT3 or GALNT6 KD, 
but only double GALNT3/GALNT6 KD was shown to inhibit 
TGFβ‑induced epithelial‑to‑mesenchymal transition (EMT) 
in prostate cancer cells (35). Similarly, our western blotting 
and consecutive MCA analyses described herein (Fig. 3) 
are strongly suggestive for a possible functional overlap and 
redundancy of GALNT3 and T6 in EOC. Based on the above 
considerations we can suggest that different GalNAc‑Ts 
perform redundant and/or overlapping functions in disease 
progression of women with HGSC. We believe that these 
relationships need to be examined further, both in vitro and 
in vivo to better understand how these transferases func‑
tion together in initiating the biosynthesis of specific target 
glycoproteins, and if they actually demonstrate compensa‑
tory methods that may enhance their implication in disease 
progression.
In conclusion, we have shown that four members of the 
GalNAc‑Ts gene family are differentially expressed in EOC 
specimens, as GALNT6, T9 and T14 were significantly over‑
expressed in both EOC cell lines and hGSCs, while GALNT2 
displayed an inversed expression pattern indicative for very 
weak or no expression in both EOC cells and EOC tumors, 
compared to relatively strong expression in HOSE cells and 
control tissues. Importantly, GALNT6 and GALNT14 expres‑
sion significantly correlated with poor prognosis of EOC 
patients with advanced disease. These data and our previously 
published data are indicative for a possible implication of 
different members of the GalNAc‑Ts gene family (including 
GALNT2, T3, T6, T9 and T14) in modulating EOC progres‑
sion, as GALNT6 and GALNT14, together with the previously 
characterized GALNT3, could represent novel prognostic EOC 
biomarkers. Moreover, our results are suggestive for overlap‑
ping functions of some GalNAc‑Ts, and especially GALNT3 
and GALNT6, in EOC, in conformity with GALNT3/T6 func‑
tional redundancy described in other cancer types. Further 
functional studies are warranted to more completely elucidate 
in vitro and in vivo the individual and/or synergistic implica‑
tions of the members of the GalNAc‑Ts gene family in ovarian 
tumorigenesis.
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